Nivasorexant

Last updated
Nivasorexant
ACT-539313 structure.png
Clinical data
Other namesACT-539313; ACT539313
Routes of
administration 		Oral
Drug class Orexin receptor antagonist
Pharmacokinetic data
Elimination half-life 3.3–6.5 hours [1] [2]
Identifiers
  • 4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(R)-3-(3-[1,2,3]triazol-2-yl-benzyl)morpholin-4-yl]methanone [3] [1]
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C23H23N7O2
Molar mass 429.484 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C=C1)C(=O)N2CCOC[C@H]2CC3=CC(=CC=C3)N4N=CC=N4)N5N=CC=N5
  • InChI=1S/C23H23N7O2/c1-17-5-6-21(22(13-17)30-26-9-10-27-30)23(31)28-11-12-32-16-20(28)15-18-3-2-4-19(14-18)29-24-7-8-25-29/h2-10,13-14,20H,11-12,15-16H2,1H3/t20-/m1/s1
  • Key:GKPHAIOJCHBZCT-HXUWFJFHSA-N

Nivasorexant (INN Tooltip International Nonproprietary Name; developmental code name ACT-539313) is an orexin antagonist medication which is under development for the treatment of binge eating disorder and was previously under development for the treatment of anxiety disorders. [4] [5] [6] [7] [1] [2]

It is an orally active small-molecule compound with an elimination half-life of 3.3 to 6.5 hours and acts as a selective orexin OX1 receptor antagonist (1-SORA). [4] [1] [2]

As of May 2022, the drug is in phase 2 clinical trials for binge eating disorder. [4] Following negative efficacy results of a phase 2 trial of nivasorexant for binge eating disorder, Idorsia (the developer of nivasorexant) signaled in May 2022 that it would not pursue further development of the drug for this indication. [8]

References

  1. 1 2 3 4 Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J (July 2020). "First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist". British Journal of Clinical Pharmacology. 86 (7): 1377–1386. doi:10.1111/bcp.14251. PMC   7319015 . PMID   32067262. ACT-539313 ((4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(R)- 3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone) is an orally active, reversible, selective OX1 receptor antagonist (1-SORA) that readily crosses the blood–brain barrier.
  2. 1 2 3 Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J (June 2021). "Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 108 110166. doi: 10.1016/j.pnpbp.2020.110166 . PMID   33159976. S2CID   226248763.
  3. ↑ Dale NC, Hoyer D, Jacobson LH, Pfleger KD, Johnstone EK (2022). "Orexin Signaling: A Complex, Multifaceted Process". Frontiers in Cellular Neuroscience. 16 812359. doi: 10.3389/fncel.2022.812359 . PMC   9044999 . PMID   35496914.
  4. 1 2 3 "ACT 539313 - AdisInsight".
  5. ↑ Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". Journal of Internal Medicine. 291 (5): 533–556. doi:10.1111/joim.13406. PMID   35043499. S2CID   248119793.
  6. ↑ Yaeger JD, Krupp KT, Gale JJ, Summers CH (December 2020). "Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity". Medicine in Drug Discovery. 8 100059. doi: 10.1016/j.medidd.2020.100059 . ISSN   2590-0986. S2CID   224861235.
  7. ↑ Caldirola D, Alciati A, Cuniberti F, Perna G (2021). "Experimental Drugs for Panic Disorder: An Updated Systematic Review". Journal of Experimental Pharmacology. 13: 441–459. doi: 10.2147/JEP.S261403 . PMC   8055642 . PMID   33889031.
  8. ↑ "Just months after its first FDA approval, Idorsia dumps binge-eating drug candidate after PhII fail".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.